Drug Discovery

The persistent challenge of managing generalized myasthenia gravis has long forced patients to rely on treatments that merely suppress symptoms rather than addressing the underlying immune dysfunction that causes debilitating muscle weakness. Kyverna Therapeutics and ElevateBio have recently

Ivan Kairatov is a seasoned expert in biopharmaceutical research and development, possessing a profound understanding of the technological shifts currently reshaping oncology. With a career dedicated to navigating the complexities of drug innovation, he has a unique perspective on how precision

The emergence of targeted therapies has fundamentally altered the trajectory of modern cancer care, yet few developments have resonated as strongly as the recent full regulatory approval of selpercatinib for adult and pediatric patients. This landmark decision by the FDA signals a profound shift in

The clinical landscape of modern oncology is undergoing a profound transformation as biotechnology firms successfully engineer specialized immune cells to target and eliminate aggressive blood cancers that have developed a resistance to conventional medical interventions. Imugene Limited, a

Modern oncology is currently witnessing a paradigm shift where the brute force of systemic chemotherapy is being replaced by sophisticated molecular delivery systems designed to spare healthy tissue. While traditional treatments often ravage the entire body to reach a localized tumor, the

The persistent challenge of treating glioblastoma multiforme has long remained one of the most formidable frontiers in modern oncology due to the aggressive nature of these tumors and the restrictive blood-brain barrier. For decades, the standard of care has relied heavily on surgical resection